Purpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy for a consecutive series of patients treated for exudativeage-related macular degeneration (ARMD). Methods: A consecutive series of 254 eyes of 127 patients received bilateral, same-dayanti-VEGF injections of either bevacizumab or ranibizumab between January 1, 2007 and July 1, 2008 and the outcomes were assessed. Approval was obtained from the InstitutionalReview Board at the University of Miami Miller School of Medicine. Results: Bilateral, same-day anti-VEGF injections were well tolerated in all patients receiving the therapy. Indication for injection was exudative macular degeneration in all patients. The incidence of adverse effects was low, with only four events reported, none of which were serious. Conclusions: In this study, bilateral anti-VEGF injections performed on the same day werepreferred over staggered injections and were well tolerated by patients. No major systemicorocular adverse events were noted, despite the presence of risk factors in a subset of patients.Given that there are serious, albeit rare, complications following anti-VEGF injection, further study with a larger number of patients will be necessary to definitively prove the safety of this treatment modality.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Sep 3 2010|
- Same-day treatment
- Visual acuity
ASJC Scopus subject areas